On-Demand Industry Webinar: Aired August 13
The Era of Immuno-Oncology in TNBC: Navigating Evidence in Early-Stage & Advanced Disease, Practicalities of Integration, and Implications for Breast Surgeons
Immunotherapy has become a new pillar in the treatment arsenal for advanced triple-negative breast cancer (TNBC), and accumulating evidence is supporting its expansion into earlier disease stages as well. To make the most of this therapeutic approach as a component of multimodal management of patients, especially in curative intent settings, it is increasingly more important for breast surgeons, medical oncologists, radiation oncologists, pathologists, and other healthcare professionals to collaborate and coordinate the care of patients with TNBC.
This PeerView Live webcast provides up-to-date information and multidisciplinary perspectives on the current and emerging roles of immune checkpoint inhibitors and combinations throughout the disease continuum of TNBC, as well as practical guidance for optimal integration of these therapies into clinical practice, focusing on the most important implications for breast surgeons.
For additional information about the program, contact PeerView at 1‑877‑833‑6141 or live@PeerView.com.
View the Presentation:
Note: This webinar is supported by Merck & Co., Inc., through an independent educational grant provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. CME credits for this program will be provided by Medical Learning Institute, Inc. It is not part of the official program of the ASBrS. This activity is free to all members.